Robert Qi Luo
About Robert Qi Luo
Robert Qi Luo is a Research Scientist II at Bristol-Myers Squibb with extensive experience in drug discovery and development, having previously worked at EMD Serono, Roche Pharmaceuticals, Merck, The Wistar Institute, and The University of South Dakota.
Current Position at Bristol-Myers Squibb
Robert Qi Luo currently holds the title of Research Scientist II at Bristol-Myers Squibb in Hopewell, NJ. His role likely involves working on innovative research projects and contributing to the company's extensive drug discovery and development programs. His experience and expertise make him an asset to the team, and he is known for his technical skills and comprehensive knowledge in biological research.
Professional Experience in Pharmaceutical Industry
Robert Qi Luo has accumulated valuable experience in the pharmaceutical industry through various roles. He has worked as a Drug Discovery Scientist at EMD Serono, Inc. in Billerica, MA, and as an Associate Principal Scientist at Roche Pharmaceuticals in Nutley, NJ. His tenure at these companies has provided him with extensive knowledge and skills in the field of drug discovery and development.
Roles at Merck and The Wistar Institute
Luo's career includes a five-year stint as a Research Biochemist at Merck in Rahway, New Jersey, and four years as a Research Assistant III at The Wistar Institute in the Greater Philadelphia Area. These positions helped him gain hands-on experience in biological research and contributed to his proficiency in various technical techniques.
Academic Background and Education
Robert Qi Luo completed a Master's degree in Microbiology from South Dakota State University from 1994 to 1997. He furthered his education at Rutgers University, where he studied Cell and Developmental Biology from 2005 to 2009. His academic background laid a solid foundation for his career in research and drug discovery.
Research and Publications
Luo has an impressive track record of research contributions, having published three first-author papers and eight co-author papers in peer-reviewed journals. His work has significantly contributed to various therapeutic programs, including those focused on fibrosis. His expertise in designing and developing in vitro, cellular, and ex vivo models has been instrumental in identifying and validating drug targets.